Biohaven’s valuation has dropped from $3.9B to $1.42B, but no revenue and high cash burn still limit its appeal. Read why ...

Biohaven Ltd. (NYSE:BHVN) is one of the Best 52-Week Low Stocks to Buy According to Analysts.. On June 10, Biohaven Ltd.

Biohaven Ltd. (NYSE:BHVN) is one of the best low priced pharma stocks to buy now. Earlier on June 10, Bexorg Inc., which is a ...

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) securities between ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BIOHAVEN LTD. (BHVN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Biohaven's preclinical pipeline includes assets targeting a wide range of central nervous system conditions and autoimmune diseases. Learn more on BHVN stock here.

Biohaven’s trial is the latest data point in the industry’s search for new ways to preserve muscle, a field of study with implications for many diseases, including SMA and obesity.

Biohaven reported that its novel next-generation trophoblast cell surface antigen 2 (Trop2) directed antibody drug conjugate (ADC), BHV-1510, demonstrated encouraging preliminary clinical activity ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad ...

Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed progress of the condition in a clinical trial.

Biohaven is studying taldefgrobep in a global Phase 3 expansion study in Spinal Muscular Atrophy (SMA), as an adjunctive therapy to enhance muscle mass and function in patients treated with ...